Description
IMC-11F8 is under investigation for its potential role in the treatment of colorectal cancer. It has shown some promise in preclinical studies and early-phase clinical trials but more research is needed to establish its efficacy and safety profile specifically in colorectal cancer patients.
Mechanism of Action
IMC-11F8 is a monoclonal antibody that targets the EphA2 receptor, which is overexpressed in various cancers including colorectal cancer.
Side Effects
Fatigue; nausea; anemia; thrombocytopenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00835185
Phase 2
Archived
Study of IMC-11F8 in Participants With Colorectal Cancer
Belgium, Spain